ChemoCentryx (CCXI) PT Raised to $64 at Raymond James
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts CCXI Hot Sheet
Price: $11.26 --0%
Rating Summary:
4 Buy, 10 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 25 | New: 2
Rating Summary:
4 Buy, 10 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 25 | New: 2
Join SI Premium – FREE
Raymond James analyst Steven Seedhouse raised the price target on ChemoCentryx (NASDAQ: CCXI) to $64.00 (from $56.00) while maintaining a Strong Buy rating.
You May Also Be Interested In
- Agility Robotics goes public on Nasdaq after SPAC merger closes
- Greatland Resources Ltd (GGP:AU) PT Lowered to AUD11.80 at Goldman Sachs
- Deutsche Bank Downgrades Amcor Plc. (AMCR) to Hold
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
